PL396313A1 - Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells - Google Patents
Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cellsInfo
- Publication number
- PL396313A1 PL396313A1 PL396313A PL39631311A PL396313A1 PL 396313 A1 PL396313 A1 PL 396313A1 PL 396313 A PL396313 A PL 396313A PL 39631311 A PL39631311 A PL 39631311A PL 396313 A1 PL396313 A1 PL 396313A1
- Authority
- PL
- Poland
- Prior art keywords
- favorably
- blood
- platelet
- plasma
- fibrinogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3616—Blood, e.g. platelet-rich plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
An autologous and allogenic fibrin carrier characterized in that it is a gel-like mixture of fibrinogen and platelet-rich plasma combined at a ratio 0.1-2 to 0.1 -2, favorably 1 : 1 of volume share, and a calcium chloride in a 0.1-99% solution, favorably a 10% solution at a ratio 0.1-2 to 0.1-2, favorably 1 : 1 relative to the mixture of fibrinogen and platelet-rich plasma. A method of obtaining an autologous fibrin carrier comprising blood collection, separation of blood plasma from blood cells, freezing and thawing of blood plasma, characterized in that the blood donation collected from the blood donor is separated from the concentrate of blood cells, i.e. erythrocytes, leukocytes being removed, said separation having the form of centrifugation at + 20 to + 24°C for 5 to 15 minutes, with centrifugation force of 700 to 2000 x g; afterwards plasma is pushed through to an empty satellite container, wherein centrifugation takes place at + 20°C to +24°C for 5-15 minutes at a centrifugation force of 2100 to 5000 x g to separate platelet-rich plasma, which is stored in bags, favorably breathable swinging bags for maximum 7 days and favorably 3 days. The remaining platelet-poor plasma is used for preparation of fibrinogen in cryoprecipitate, by freezing blood plasma twice to the temperature of -30°C to -90°C and thawing blood plasma at about + 4°C, for example in a water bath, then it is centrifuged at about + 4°C for 5-20 minutes at centrifugation force of 1000 to 5000 x g, wherein supernatant is removed and resultant cryoprecipitate is mixed with platelet-rich plasma from the container, at a ratio from 0.1 -2 to 0.1 -2, favorably 1 : 1, and with a calcium compound solution, favorably a 10% calcium chloride solution at a favorable ratio 1 : 1 relative to the mixture of fibrinogen and platelet-rich plasma. Use of an autologous fibrin carrier for obtaining a gel-like transplant, that is a carrier formed by mixing fibrinogen and platelet-rich plasma obtained from the recipient's blood, favorably of a single donation, or ready-made fibrinogen characterized by an adequate phenotype and platelet-rich plasma taken directly from the blood donation of the patient-recipient using the operating room's apparatus, wherein in the process of obtaining a carrier and prior to the addition of a 0.1%-99% calcium chloride solution at a ratio 0.1 -2 do 0.1-2, favorably 1 : 1 of volume share relative to the mixture of fibrinogen and platelet-rich plasma, from 5 thousand to 100 million recipient's cells or allogenic and xenogenic cells are added, cultured in a known way and processed on the transplantation's date by trypsinization, washing in a serum- containing medium and vitality assessment.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL396313A PL218235B1 (en) | 2011-09-12 | 2011-09-12 | Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells |
PCT/PL2012/000029 WO2013039411A1 (en) | 2011-09-12 | 2012-04-30 | Autologous and allogenic fibrin carrier, method of obtaining thereof and use of a fibrin carrier for transplantation of cells, particularly human cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL396313A PL218235B1 (en) | 2011-09-12 | 2011-09-12 | Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells |
Publications (2)
Publication Number | Publication Date |
---|---|
PL396313A1 true PL396313A1 (en) | 2013-03-18 |
PL218235B1 PL218235B1 (en) | 2014-10-31 |
Family
ID=46229905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL396313A PL218235B1 (en) | 2011-09-12 | 2011-09-12 | Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells |
Country Status (2)
Country | Link |
---|---|
PL (1) | PL218235B1 (en) |
WO (1) | WO2013039411A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL446279A1 (en) * | 2023-09-30 | 2024-04-22 | Keymed Spóła Z Ograniczoną Odpowiedzialnością | Kit for producing an autologous dressing from blood, dressing, method of its production and its application |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL231230A0 (en) * | 2014-02-27 | 2014-08-31 | Omrix Biopharmaceuticals Ltd | Fibrinogen formulation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL54175Y1 (en) | 1992-10-01 | 1996-06-28 | Tomasz Nowakowski | Cake baking mould |
US5674394A (en) * | 1995-03-24 | 1997-10-07 | Johnson & Johnson Medical, Inc. | Single use system for preparation of autologous plasma |
CN101053679B (en) * | 2007-04-17 | 2010-05-26 | 浙江大学 | Method for preparing polymer multiporous holder filled with fiber protein gel |
CN101221186A (en) * | 2007-12-14 | 2008-07-16 | 天津理工大学 | Fibrin gel with protein recognition function and its preparing method |
PL388247A1 (en) | 2009-06-10 | 2010-12-20 | Danuta Foicik | Dispensing screw-cap |
-
2011
- 2011-09-12 PL PL396313A patent/PL218235B1/en unknown
-
2012
- 2012-04-30 WO PCT/PL2012/000029 patent/WO2013039411A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL446279A1 (en) * | 2023-09-30 | 2024-04-22 | Keymed Spóła Z Ograniczoną Odpowiedzialnością | Kit for producing an autologous dressing from blood, dressing, method of its production and its application |
Also Published As
Publication number | Publication date |
---|---|
WO2013039411A1 (en) | 2013-03-21 |
PL218235B1 (en) | 2014-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dessels et al. | Making the switch: alternatives to fetal bovine serum for adipose-derived stromal cell expansion | |
CN105638642B (en) | A kind of immunocyte frozen stock solution and its application | |
Schallmoser et al. | Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells | |
Bieback et al. | Clinical protocols for the isolation and expansion of mesenchymal stromal cells | |
Gulliksson | Defining the optimal storage conditions for the long-term storage of platelets | |
ES2880718T3 (en) | Combined umbilical cord blood NK cells and their uses for the treatment of cancer and chronic infectious diseases | |
JP2009533059A5 (en) | ||
WO2013111130A1 (en) | A system and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma(prp) | |
Solomon et al. | Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation | |
MY160835A (en) | System for purifying certain cell populations in blood or bone marrow by depleting others | |
KR20220004086A (en) | Systems and methods for extraction and cryopreservation of bone marrow | |
KR20110036644A (en) | Method for controlling propagation of umbilical cord blood hematopoietic stem cells and use thereof | |
Antoninus et al. | Human platelet lysate enhances the proliferation of Wharton's jelly-derived mesenchymal stem cells | |
GB2574333A (en) | Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma | |
US11589575B2 (en) | Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood | |
CN102686725A (en) | Expansion medium for CD34-negative stem cells | |
PL396313A1 (en) | Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells | |
CN107072189B (en) | Composition for improving stability of stem cells | |
CN109423476A (en) | It is used to prepare the kit of fat mesenchymal stem cell | |
US20220186187A1 (en) | Compositions and methods for extraction of mesenchymal stem cells | |
WO2019100175A1 (en) | Composition and method for the cultivation, expansion, preservation and/or pre-treatment of cells | |
CA2893828A1 (en) | Point of care isolation and concentration of blood cells | |
Martinaud et al. | In vitro characteristics of cryopreserved platelet concentrates reconstituted by fresh frozen or lyophilized plasma | |
Lee | Clinical utilization of cord blood over human health: experience of stem cell transplantation and cell therapy using cord blood in Korea | |
CA2977202A1 (en) | Improved photodynamic process and product obtained therefrom |